Fluticasone Propionate

Introduction Overview

Generic Name

fluticasone propionate

Brand Name

Xhance

Dosage Form

metered nasal spray

Drug Class

nasal steroids

Pharmacokinetics

Absorption:
Fluticasone propionate delivered by XHANCE nasal spray exhibits low systemic bioavailability due to extensive first-pass metabolism and limited absorption through nasal mucosa. Peak plasma concentrations (Cmax) following 186 mcg dose during exhalation averaged 17.2 pg/mL with an AUC0-∞ of 111.7 pg·h/mL, while a 372 mcg dose yielded Cmax of 25.3 pg/mL and AUC of 171.7 pg·h/mL in healthy subjects. In patients with mild to moderate asthma, a 372 mcg dose resulted in slightly higher systemic exposure (Cmax 28.7 pg/mL, AUC 222.6 pg·h/mL), indicative of variable absorption potentially influenced by airway condition.

Distribution:
Intravenously administered fluticasone propionate demonstrates rapid initial distribution due to high lipid solubility and tissue affinity, with an average volume of distribution of 4.2 L/kg. Plasma protein binding is very high (~99%), primarily to albumin, with weak reversible erythrocyte binding and negligible transcortin interaction, suggesting stable plasma transport. The localized nasal delivery by XHANCE impacts mucosal exposure differently based on the exhalation delivery system, promoting deeper nasal deposition and potentially enhancing local tissue distribution.

Metabolism:
Fluticasone propionate is extensively metabolized primarily via hepatic cytochrome P450 3A4 (CYP3A4) to inactive 17β-carboxylic acid derivatives. These metabolites demonstrate markedly reduced glucocorticoid receptor affinity (~1/2000 that of parent drug) and negligible pharmacologic activity. No active circulating metabolites are detected in humans. In vitro studies with human hepatoma cells identified additional metabolites not observed clinically, highlighting the metabolic specificity in vivo.

Elimination:
Following systemic administration, fluticasone propionate clearance is rapid and follows polyexponential kinetics, with an elimination half-life of approximately 7.8 hours. Total blood clearance is high at ~1093 mL/min, with renal excretion accounting for less than 0.02% of administered dose. The majority of the drug and its metabolites are eliminated via fecal excretion, consistent with biliary clearance pathways. The low systemic absorption and rapid metabolism minimize systemic accumulation under recommended dosing.

Specific Populations:
Pharmacokinetic data show no significant differences in clearance or exposure across racial or ethnic groups. Data are lacking for pediatric populations, with XHANCE not studied in children. Hepatic impairment may increase systemic exposure due to reduced metabolism, necessitating close monitoring, while no formal renal impairment studies are available.

Dosage Forms

Available Dosage Forms:
XHANCE is supplied as a metered nasal spray delivering 93 micrograms (mcg) of fluticasone propionate per spray. Each bottle contains 16 mL of aqueous suspension, providing 120 metered sprays. The formulation includes microcrystalline cellulose, carboxymethylcellulose sodium, dextrose, benzalkonium chloride, polysorbate 80, edetate disodium dihydrate, sodium hydroxide and hydrochloric acid (for pH adjustment), and purified water.

Dosages for Adults and Adolescents:
The recommended dosage for adults is either 186 mcg (1 spray per nostril) or 372 mcg (2 sprays per nostril) administered twice daily, not to exceed a total daily dose of 744 mcg (2 sprays per nostril twice daily). Administration requires shaking before use, proper priming (7 sprays initially, 2 sprays if unused for ≥7 days), and use of the specialized exhalation delivery mechanism.

Specific Patient Populations:
Safety and efficacy have not been established in pediatric patients; therefore, use is not recommended. Patients with hepatic impairment require close monitoring due to the potential for increased systemic exposure. No dosage adjustment guidance is available for geriatric or renal impairment populations. Regular assessments for nasal mucosal integrity and other adverse effects are advised, especially in patients with prior nasal surgery or trauma.

Additional Administration Details:
The exhalation delivery system requires simultaneous exhalation into the mouthpiece with actuation of the spray into the nostril, enhancing drug deposition in the nasal cavities. Patients are instructed to avoid spraying directly on the nasal septum to minimize risk of mucosal injury.

Mechanism Of Action

Fluticasone propionate, the active ingredient in XHANCE, is a synthetic trifluorinated corticosteroid exhibiting potent anti-inflammatory activity primarily via high-affinity binding to intracellular glucocorticoid receptors. Its receptor binding affinity is 18 times greater than dexamethasone and surpasses other commonly used corticosteroids, enabling effective modulation of inflammatory pathways even at low local concentrations.

Upon binding to the glucocorticoid receptor, the activated receptor complex translocates to the nucleus where it regulates the transcription of numerous anti-inflammatory genes while repressing pro-inflammatory gene expression. These molecular actions lead to decreased production and release of a wide array of inflammatory mediators including cytokines, histamine, eicosanoids, leukotrienes, and neuropeptides. Additionally, fluticasone propionate diminishes recruitment and activation of inflammatory cells such as eosinophils, mast cells, neutrophils, macrophages, and lymphocytes within the nasal mucosa.

The exhalation delivery system of XHANCE introduces carbon dioxide-rich breath during drug administration, which may further modulate inflammatory cell mediator activity and neuropeptide signaling possibly through alterations in local pH, nitric oxide clearance, and positive nasal pressure—factors hypothesized to contribute to enhanced efficacy in chronic rhinosinusitis treatment. The precise clinical relevance and mechanisms underlying these effects warrant further investigation.

Clinically, this potent anti-inflammatory action translates into significant reductions in nasal mucosal eosinophils and basophils in treated patients, contributing to decreased nasal polyp size and relief of congestion and other rhinosinusitis symptoms. Compared to other nasal corticosteroids like budesonide or beclomethasone, fluticasone propionate via the XHANCE delivery system demonstrates superior receptor affinity and novel administration technique to optimize nasal deposition, potentially improving therapeutic outcomes in both CRSwNP and CRSsNP.

Pharmacological Actions

Potent anti-inflammatory effects mediated through high-affinity binding to glucocorticoid receptors.
Inhibition of inflammatory mediator release including cytokines, histamine, leukotrienes, and eicosanoids.
Reduction of inflammatory cell infiltration such as eosinophils, mast cells, neutrophils, macrophages, and lymphocytes in nasal mucosa.
Local nasal vasoconstriction reducing mucosal edema and congestion.
Suppression of immune response potentiating risk for infections.
High topical potency with limited systemic bioavailability due to rapid metabolism.
Modulation of neuropeptide signaling potentially enhanced by exhalation delivery system.
Minimal active metabolites minimizing systemic corticosteroid side effects.

Therapeutic Or Clinical Uses

Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.
Treatment of chronic rhinosinusitis without nasal polyps (CRSsNP) in adults.
Reduction of nasal congestion and obstruction associated with chronic rhinosinusitis.
Improvement of nasal polyp size and associated symptoms such as nasal congestion and loss of smell.
Adjunctive therapy for patients with moderate to severe nasal polyposis refractory to standard nasal corticosteroids.
Management of inflammation in nasal and paranasal sinus mucosa to prevent recurrence or exacerbation.
Symptomatic relief in patients with chronic sinonasal inflammatory disease.
Potential use in patients with prior inadequate response to conventional nasal corticosteroid sprays, due to enhanced nasal deposition.

Side Or Adverse Effects

Epistaxis (nosebleeds), commonly reported with incidence up to 11.9% in treated patients.
Nasal septal ulcerations and erosions, sometimes leading to pain or discomfort.
Nasal septal perforation, particularly in patients with prior nasal surgery or trauma.
Nasal mucosal erythema and congestion.
Nasopharyngitis and pharyngitis representing upper respiratory tract irritation or infection.
Headache occurring in a subset of patients.
Candida albicans localized infections in nasal and oropharyngeal mucosa.
Impaired nasal wound healing, contraindicating use in patients with recent nasal trauma or surgery until healed.
Potential ocular effects including glaucoma and cataracts with long-term use.
Hypersensitivity reactions including anaphylaxis, angioedema, urticaria, rash, bronchospasm, and hypotension.
Systemic corticosteroid effects such as hypercorticism and adrenal suppression in susceptible individuals or high-dose exposure.
Rare reports of systemic effects upon interaction with strong CYP3A4 inhibitors.
Possible reduction in bone mineral density with chronic use and prolonged exposure.
Potential impact on growth velocity in pediatric patients (not established for XHANCE pediatric use).
Local nasal discomfort, dryness, and irritation post administration.

Precautions

Avoid spraying directly on the nasal septum to reduce risk of mucosal injury and perforation.
Use caution in patients with recent oropharyngeal or nasal surgery, trauma, or ulceration until healed.
Monitor patients periodically for nasal mucosal adverse effects during long-term therapy.
Consider ophthalmologic monitoring for patients at risk of or developing ocular symptoms related to corticosteroid use.
Use with caution in patients with active or quiescent infections including tuberculosis and ocular herpes simplex.
Avoid exposure to chickenpox or measles during corticosteroid therapy; initiate prophylaxis if exposed.
Taper corticosteroid dose slowly when discontinuing to minimize risk of adrenal insufficiency.
Monitor for systemic corticosteroid adverse effects in patients receiving concomitant therapies that may increase systemic exposure.
Evaluate patients at risk for decreased bone mineral density periodically and consider appropriate interventions.
Not recommended for use in pediatric patients, as safety and effectiveness are not established.
Use cautiously in hepatic impairment due to potential accumulation and increased systemic effects.
Patients with hypersensitivity reactions or known allergy to any ingredient should not use XHANCE.
Counsel patients on proper administration technique to maximize therapeutic effect and minimize irritation.
Advise patients to maintain regular use for optimal benefit and not to exceed recommended doses.
Patients should report any vision changes, nasal symptoms or signs of infection promptly.

Warnings

Local nasal adverse reactions including epistaxis, nasal ulceration, erosion, and septal perforation occur with risk increased over placebo.
Candida albicans infections localized to nasal and oropharyngeal mucosa have been reported.
Glaucoma and cataracts may develop with long-term use; patients should be monitored for ocular effects.
Hypersensitivity reactions such as anaphylaxis, angioedema, urticaria, rash, bronchospasm, and hypotension may occur; discontinue drug if these arise.
Increased susceptibility to infections including tuberculosis, fungal, bacterial, viral, or parasitic infections in immunocompromised patients.
Risk of hypercorticism and adrenal suppression, particularly when doses are exceeded or in susceptible individuals.
Avoid use or closely monitor patients taking strong CYP3A4 inhibitors due to increased risk of systemic corticosteroid effects.
Potential reduction in bone mineral density with prolonged corticosteroid use.
Growth retardation may occur in pediatric patients, though safety in children has not been established for this product.
Inadequate adrenal response during stress (trauma, surgery, infection) may occur; monitor patients accordingly.
Avoid overdosage as signs of hypercorticism and adrenal suppression may ensue.
Patients with recent nasal surgery, trauma, or ulcerations should avoid use until healed to prevent impaired wound healing.
The safety and effectiveness of using XHANCE in excess of recommended doses have not been studied.
Instruct patients to carefully follow administration instructions to avoid adverse events.
Discontinue treatment if nasal septal perforation occurs.

Contraindication

Hypersensitivity to fluticasone propionate or any components of the XHANCE formulation.
Known allergy or hypersensitivity reactions including anaphylaxis to corticosteroids contraindicate use.
Avoid use in patients with active untreated nasal infections or nasal ulcers until properly treated.
Use contraindicated in patients with known nasal septal perforation prior to therapy initiation.
Avoid in individuals with known intolerance to preservatives or excipients such as benzalkonium chloride used in the formulation.

Drug Interactions

Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, atazanavir, clarithromycin) increase systemic exposure of fluticasone propionate, potentially causing systemic corticosteroid adverse effects.
Ritonavir coadministration significantly increases plasma fluticasone concentrations and decreases serum cortisol, risking adrenal suppression.
Ketoconazole coadministration moderately increases fluticasone systemic exposure and decreases cortisol AUC.
Use with strong CYP3A4 inhibitors is generally not recommended during XHANCE therapy.
No significant pharmacokinetic interactions observed with erythromycin coadministration.
Potential additive effects with systemic corticosteroids increasing risk of hypercorticism.
Concurrent use with immunosuppressive agents may increase risk of infections.
Drugs affecting CYP3A4 enzyme activity may alter fluticasone propionate metabolism and systemic exposure.
Patients on antifungal or anti-HIV medications should be closely monitored for systemic corticosteroid effects.
No data on interactions with other nasal or inhaled corticosteroids; cautious cumulative exposure should be evaluated.
Potential interaction with other nasal medications not established; consider clinical judgement when coadministered.
Monitor patients for signs of systemic corticosteroid excess when used with interacting drugs.

Preparations Of The Drug

XHANCE nasal spray is provided in an amber glass bottle fitted with a metered-dose spray pump inside a proprietary OptiNose exhalation delivery system.
Each bottle contains 16 mL aqueous suspension of fluticasone propionate at 93 mcg per spray.
The device includes a cone-shaped nasal applicator for deep nasal delivery and a flexible mouthpiece for exhalatory airflow.
The spray pump delivers 120 metered sprays per bottle after proper priming.
Formulated with microcrystalline cellulose, carboxymethylcellulose sodium, dextrose, benzalkonium chloride (preservative), polysorbate 80, edetate disodium dihydrate, and pH adjusting agents.
Dispensed in cartons containing one prefilled XHANCE unit per pack.
Packaged with detailed instructions for use to ensure proper administration technique.
Storage requires room temperature (15°C to 25°C) with permitted excursions up to 30°C; protect from extreme heat, cold, and light.
Bottle base is non-removable; the intact device should be discarded after 120 sprays to ensure dose accuracy.
Identifiable by orange cap covering both nasal and mouthpieces.
Distributed by OptiNose US, Inc., with registered trademark protections.
Patient labeling and FDA-approved instructions accompany the product to promote safe and effective use.